MEK Inhibitor–Immunotherapy in Cholangiocarcinoma: Hepatology | July 2026

Introduction:

Advanced cholangiocarcinoma (CCA) remains difficult to treat, with limited benefit from current chemotherapy and immunotherapy combinations. This study investigated whether combining a MEK inhibitor (MEKi), anti-PD-L1 therapy, and a CD27 agonist could improve antitumor immunity and whether the tumor microenvironment influences treatment response.

Why was this study needed?

• Most patients with advanced CCA develop resistance to current immunotherapy.
• Early clinical trials combining MEKi with immunotherapy have shown disappointing results.
• The mechanisms of resistance to immunotherapy remain poorly understood.
• The impact of tumor location on treatment response has not been adequately explored.
• More effective combination immunotherapy strategies are urgently needed.

Results:

• Triple therapy (MEKi + anti-PD-L1 + CD27 agonist) significantly enhanced antitumor immunity and tumor control in subcutaneous CCA models, increasing CD8⁺ memory T-cell infiltration.
• In orthotopic liver tumors, however, therapeutic benefit was substantially reduced because of abundant immunosuppressive myeloid cells, highlighting the profound influence of the liver tumor microenvironment.
• Targeting these myeloid cells unexpectedly caused severe systemic and hepatic inflammation, emphasizing that overcoming immune suppression may also increase treatment-related toxicity.

Clinical Impact:

This study demonstrates that tumor location is a major determinant of immunotherapy efficacy in cholangiocarcinoma. It also highlights the importance of using physiologically relevant liver tumor models during drug development, as results obtained in subcutaneous models may overestimate clinical benefit.

Bottom Line:

The liver tumor microenvironment profoundly influences immunotherapy response in cholangiocarcinoma. While MEKi + anti-PD-L1 + CD27 agonist therapy shows promise, future strategies must carefully balance enhancing T-cell immunity while safely modulating immunosuppressive myeloid cells.